The BCL-2 arbiters of apoptosis and their growing role as cancer targets.

Adams JM, Cory S. · 2018

Read The BCL-2 arbiters of apoptosis and their growing role as cancer targets. by Adams JM, Cory S. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5729526.txt.

Introduction

Adams and Cory review the BCL-2 protein family and its role in cancer. These proteins act as judges of apoptosis, the orderly death of cells. Faulty death control helps tumors grow and resist standard drugs. The review explains how family members interact to switch death on or off.

The authors then cover BH3 mimetic drugs, which copy natural blockers of survival proteins. Venetoclax, a BCL-2 blocker, won approval for a hard to treat form of leukaemia. Trials now test it in many other cancers. Newer drugs that target MCL-1 may help cancers that resist venetoclax.

Catalog record

CREATORAdams JM, Cory S.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE64 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5729526

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The BCL-2 arbiters of apoptosis and their growing role as cancer targets By Jerry M Adams, Suzanne Cory Published in: Cell Death and Differentiation DOI: 10.1038/cdd.2017.161 ABSTRACT Abstract Impaired apoptosis plays a central role in cancer development and limits the efficacy of conventional cytotoxic therapies. Deepening understanding of how opposing factions of the BCL-2 protein family switch on apoptosis and of their structures has driven development of a new class of cancer drugs that targets various pro-survival members by mimicking their natural inhibitors, the BH3-only proteins. These ‘BH3 mimetic’ drugs seem destined to become powerful new weapons in the arsenal against cancer. Successful clinical trials of venetoclax/ABT-199, a specific inhibitor of BCL-2, have led to its approval for a refractory form of chronic lymphocytic leukaemia and to scores of on-going trials for other malignancies. Furthermore, encouraging preclinical studies of BH3 mimetics that target other BCL-2 pro-survival members, particularly MCL-1, offer promise for cancers resistant to venetoclax. This review sketches the impact of the BCL-2 family on cancer development and therapy, describes how interactions of family members trigger apoptosis and discusses the potential of BH3 mimetic drugs to advance cancer therapy. Graphical Abstract FACTS - Three factions of the BCL-2 protein family interact to adjudicate whether cells undergo apoptosis. The process is initiated when BH3-only proteins, upregulated by diverse stress signals, engage the surface groove of pro-survival relatives (for example, BCL-2, BCL-XL, MCL-1), preventing their constraint of BAX and BAK, which then form oligomers that perforate the outer mitochondrial membrane to elicit caspase activation. - Diverse tumours have defects in activation of apoptosis because of overexpression of BCL-2 pro-survival proteins or impaired upregulation of BH3-only proteins due to, for example, inactivation of the p53 pathway. - As a new approach to cancer therapy, drugs termed ‘BH3 mimetics’ that tightly bind the surface groove of certain pro-survival BCL-2 proteins have been developed. - Venetoclax, a potent BCL-2-specific BH3 mimetic, has been approved for treatment of a refractory form of chronic lymphocytic leukaemia and is under trial for many other malignancies, both as a single agent and in combination with diverse known anticancer agents. - Genetic data and preclinical studies predict that recently developed BH3 mimetics specifically targeting MCL-1 will be efficacious against multiple haemopoietic malignancies and sensitise some solid tumours to other agents. OPEN QUESTIONS - As certain normal cell populations are sensitive to diminished levels of BCL-XL or MCL-1, can an acceptable therapeutic window be found for their inhibitors? - Given that most current trials of BH3 mimetics have focussed on haemopoietic malignancies, will the new drugs also have a major role in treating solid tumours? - Which combinations of BH3 mimetics, either with each other or with other targeted or conventional agents, will be most efficacious for different malignancies? - Can BH3 mimetic therapy provide protracted remissions without the need for long-term treatment? - Will increased understanding of BAX and BAK oligomers and the elusive apoptotic pore suggest additional ways to target the apoptotic switch for cancer therapy? The FDA approval in 2016 of venetoclax (also known as ABT-199) for treating a refractory form of chronic lymphocytic leukaemia (CLL) was a significant milestone for cancer research and therapy. The remarkable clinical performance of this drug, designed to mimic natural triggers of apoptosis, capped three decades of research on the BCL-2 protein family. In this review, we reflect on the discovery of BCL-2 and its relatives, summarise how they regulate apoptosis and describe how this knowledge drove the development of BH3 mimetic anticancer drugs. We then sketch the clinical findings that led to FDA approval of venetoclax and discuss its potential and that of other emerging BH3 mimetics, particularly those targeting MCL-1. In addition to the articles in this series,1, 2, 3, 4, 5, 6 other recent reviews assess the clinical impact of BH3 mimetics and BCL-2 family function.7, 8, 9, 10 APOPTOSIS AND ITS FIRST KNOWN INHIBITOR: BCL-2 In vertebrates, apoptosis both shapes the embryo and ensures homeostasis within adult tissues. During apoptosis, cells shrink, fragment their DNA, bleb and break up into ‘apoptotic bodies’ for engulfment by phagocytes.11 Importantly, because the plasma membrane is not breached, no inflammation ensues. Apoptosis culminates in activation of cysteine proteases called caspases that cleave vital cellular proteins. Caspases are activated through either the ‘extrinsic’ apoptosis pathway, triggered by engagement of cell surface ‘death receptors’ of the tumour necrosis factor (TNF) receptor family, or the ‘intrinsic’ pathway, initiated by diverse cellular stresses. The BCL-2 protein family regulates the latter, by controlling the integrity of the mitochondrial outer membrane (MOM). BCL-2 was the first inhibitor of apoptosis to be discovered, in any species. The gene was found linked to the immunoglobulin heavy chain gene locus by the t(14;18) chromosome translocation that hallmarks human follicular lymphoma (FL).1 Although BCL-2 seemed likely to be a new oncoprotein, its sequence provided no clues about its function. In 1988, Vaux et al.12 solved the mystery by showing that lymphocytes forced to express elevated BCL-2 resisted apoptosis when deprived of their requisite cytokine. This seminal study revealing BCL-2 as the prototypic inhibitor of cell death also established, for the first time, that cytokines signal cell survival and proliferation by different pathways and that impaired apoptosis contributes to malignant transformation. BCL-2 transgenic mice reinforced and extended these observations. The excess lymphocytes they accumulated had failed to die in response to physiological cues and resisted diverse cytotoxic agents, including chemotherapeutic drugs.13, 14, 15, 16 Notably, mice co-expressing BCL-2 and myc transgenes developed lymphomas markedly faster than littermates expressing either transgene alone,17 validating BCL-2 as an oncogene. Clarifying the basis for the synergy with myc, enforced MYC expression proved to stimulate apoptosis.18, 19 Thus, by blocking apoptosis, BCL-2 removes a critical brake on MYC-driven proliferation and oncogenesis. As t(14;18) translocations can be detected in B cells of healthy humans,20 follicular lymphoma requires mutations additional to BCL-2 translocation, and perhaps also chronic T-cell stimulation.21 Several other human malignancies express elevated BCL-2 because of diverse mechanisms. Notably, the high BCL-2 in CLL reflects loss of microRNAs that normally dampen translation of its messenger RNA.1 THE BCL-2 PROTEIN FAMILY Vertebrate proteins related to BCL-2 bear from one to four BCL-2 Homology (BH) domains and fall into three functional factions (Figure 1a). The closest BCL-2 relatives (BCL-XL, BCL-W, MCL-1, A1/BFL-1 and, in humans, BCL-B) promote cell survival, but BAX and BAK (and possibly BOK) instead promote cell death, as do distant relatives termed BH3-only proteins, because their only homology to BCL-2 (or each other) is the BH3 domain, through which they engage multi-BH domain relatives. [Figure: The BCL-2 protein family. (a) The initiator, guardian and effector factions of the family. Domains of shared BCL-2 Homology (BH), and the nine α-helices in the multi-BH domain members are indicated. (Effectors BAX and BAK, and the related BOK, have a BH4 domain if both structural and sequence homology are considered.29) BOK seems to drive apoptosis only in special circumstances.6 Faction members most important for controlling apoptosis are in bold. All multi-BH domain family members and some BH3-only proteins (BIM, BID, BIK, HRK) have a C-terminal transmembrane (TM) domain for anchoring to organelles, most notably the MOM. (b) How the BCL-2 protein family controls cell life and death is shown. In

Read the complete text